Vilsboll T, et al. - In this study, investigators quantified data to determine the consequences of insulin degludec/liraglutide fixed-ratio combination (IDegLira) vs comparators on cardiovascular (CV) risk markers from DUAL II vs insulin degludec, DUAL V vs insulin glargine 100 units/mL, and DUAL VII vs basal-bolus therapy in subjects adjusted for sex, age (< 65 years vs ≥ 65 years), and duration of diabetes (< 10 years or ≥ 10 years). In all, treatment outcomes favored IDegLira in many cases for variations from baseline in HbA1c, body weight, systolic blood pressure, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol. They investigators observed higher heart rates and diastolic blood pressure levels with IDegLira vs comparators in males. Findings supported an association of IDegLira with a general improvement in CV risk markers vs basal insulin or basal-bolus therapy after 26 weeks of treatment.